Data / Research funding / Emerging Infectious Diseases
Emerging Infectious Diseases: 8,317 NIH awards ($15.6B) to 1,002 organizations
8,317 NIH awards ($15.6B) in the NIH spending category Emerging Infectious Diseases, to 1,002 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 8,317 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $965,792,899 | June 15, 2020 | June 30, 2026 | THOMAS, SONIA M | reporter.nih.gov |
| OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $650,978,035 | May 24, 2021 | May 23, 2025 | KATZ, STUART D | reporter.nih.gov |
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $472,070,715 | December 1, 2024 | November 30, 2025 | CURRIER, JUDITH S. | reporter.nih.gov |
| HIV Vaccines Clinical Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $244,071,463 | June 29, 2006 | November 30, 2027 | COREY, LAWRENCE | reporter.nih.gov |
| HIV Vaccine Trials Network Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $177,480,054 | June 29, 2006 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $156,469,927 | March 30, 2022 | March 31, 2022 | COREY, LAWRENCE | reporter.nih.gov |
| Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases: Mpox Clinical Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $150,331,625 | March 1, 2021 | February 28, 2026 | EWELL, MARIAN | reporter.nih.gov |
| RADx-UP CDCC | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $96,490,468 | September 27, 2020 | June 30, 2025 | COHEN-WOLKOWIEZ, MICHAEL | reporter.nih.gov |
| NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE: AVIAN INFLUENZA RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $91,354,067 | April 1, 2021 | January 14, 2027 | WEBBY, RICHARD | reporter.nih.gov |
| AI-driven Structure-enabled Antiviral Platform (ASAP) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $89,845,851 | May 16, 2022 | August 31, 2027 | CHODERA, JOHN DAMON | reporter.nih.gov |
| CLINICAL RESEARCH OPERATIONS AND MANAGEMENT SUPPORT (CROMS) - SARS CoV-2 Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $86,825,316 | April 17, 2017 | April 16, 2024 | HOLMES, MELYNDA | reporter.nih.gov |
| Statistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $84,840,845 | June 29, 2006 | November 30, 2027 | HUGHES, MICHAEL DAVID | reporter.nih.gov |
| Antibacterial Resistance Leadership Group (ARLG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $78,031,274 | June 1, 2013 | November 30, 2026 | FOWLER, VANCE G. | reporter.nih.gov |
| IMPAACT Leadership Group | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $77,468,129 | December 1, 2024 | November 30, 2027 | NACHMAN, SHARON A | reporter.nih.gov |
| COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $72,825,966 | September 10, 2019 | September 24, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| COVID-19: NIAID Regulatory Support Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $63,227,516 | April 15, 2023 | April 14, 2024 | RAFI, ASIMAH | reporter.nih.gov |
| Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $63,155,364 | December 5, 2019 | November 30, 2026 | STEPHENS, DAVID S | reporter.nih.gov |
| Microbiology and Infectious Diseases Biological Resource Repository (MID-BRR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $63,039,784 | May 5, 2022 | October 31, 2023 | WILLIAMS, CARLA | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $62,580,113 | April 1, 2021 | September 17, 2026 | GARCIA-SASTRE, ADOLFO | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $61,029,344 | September 30, 2019 | March 31, 2027 | URDAHL, KEVIN | reporter.nih.gov |
| SDMC - IMPAACT Leadership Group | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $59,233,299 | June 29, 2006 | November 30, 2027 | SHAPIRO, DAVID ERIC | reporter.nih.gov |
| CoVPN 5001 - A prospective study of acute immune responses to SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $57,987,348 | March 21, 2022 | March 31, 2022 | GILBERT, PETER B. | reporter.nih.gov |
| AIDS Clinical Trial Group Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $56,714,107 | January 1, 2014 | November 30, 2027 | ALDROVANDI, GRACE M | reporter.nih.gov |
| HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $54,331,950 | March 18, 2022 | March 31, 2022 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| CIVIC: University of Georgia Center for Influenza Vaccine Research in High Risk Populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $53,879,677 | September 10, 2019 | September 9, 2026 | ROSS, TED | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $52,452,735 | September 10, 2019 | September 9, 2026 | MOODY, TONY | reporter.nih.gov |
| Tulane National Primate Research Center | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $52,341,995 | May 9, 1997 | April 30, 2028 | HAMM, L LEE | reporter.nih.gov |
| CEIRR: CORONAVIRUS RESEARCH ACTIVITIES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $50,650,417 | April 1, 2021 | September 29, 2026 | HENSLEY, SCOTT | reporter.nih.gov |
| DMID Clinical Research Operations & Management Support (CROMS): mpox activities | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $47,983,949 | April 1, 2024 | March 31, 2026 | ELLIS, JESSICA | reporter.nih.gov |
| Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,959,734 | August 13, 2025 | November 30, 2026 | KOTLOFF, KAREN L. | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component B: Vaccine Manufacturing and Toxicology Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,296,051 | August 26, 2019 | March 13, 2028 | DENNY, THOMAS | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $38,435,039 | September 30, 2019 | September 29, 2026 | FORTUNE, SARAH | reporter.nih.gov |
| Vanderbilt Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $36,564,580 | December 11, 2019 | November 30, 2026 | CREECH, CLARENCE BUDDY | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $35,184,139 | August 1, 2021 | July 31, 2026 | COLER, RHEA | reporter.nih.gov |
| West Virginia Clinical and Translational Science Institute: A Statewide Organization Building Research Excellence and Engaging Communities to Improve Health | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $31,832,071 | August 15, 2012 | June 30, 2027 | HODDER, SALLY LYNN | reporter.nih.gov |
| SECURE PLATFORMS SUPPORT FOR THE N3C DATA ENCLAVE (COVID-19) | NIH | National Institute on Drug Abuse | 2021 to 2023 | $30,357,494 | August 2, 2023 | September 24, 2023 | MARIZAN-HO, JOHANNA | reporter.nih.gov |
| DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $30,010,720 | May 2, 2019 | April 30, 2027 | WEBBY, RICHARD JOHN | reporter.nih.gov |
| Task V15: Development of Assays and Reagents for mpox Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $28,751,383 | September 1, 2022 | April 30, 2026 | RUDGE, THOMAS | reporter.nih.gov |
| RADX-TECH - LUMINOSTICS, INC. SMARTPHONE-BASED TEST FOR RAPID SARS-COV-2 ANTIGEN DETECTION FROM NASAL SWABS | NIH | National Heart, Lung, and Blood Institute | 2021 | $28,624,460 | September 30, 2020 | September 29, 2021 | RAJA, BALA | reporter.nih.gov |
| STSS: SMART IRB ONLINE RELIANCE SYSTEM (ORS) AND JOINDER ENHANCEMENTS SUPPORT SERVICES | NIH | National Institute on Drug Abuse | 2021 to 2022 | $27,880,093 | April 15, 2022 | April 14, 2023 | MAYS, GARY | reporter.nih.gov |
| Northern New England Clinical and Translational Research Network | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $27,379,043 | July 3, 2017 | June 30, 2027 | ROSEN, CLIFFORD JAMES | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response (CEIRR): Avian Influenza Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,250,171 | April 1, 2021 | January 14, 2027 | LOWEN, ANICE | reporter.nih.gov |
| Louisiana Clinical and Translational Science Center | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $25,457,946 | August 15, 2012 | June 30, 2027 | KIRWAN, JOHN P. | reporter.nih.gov |
| Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,789,202 | May 15, 2019 | April 30, 2027 | STAAT, MARY A | reporter.nih.gov |
| University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,477,809 | February 1, 2007 | November 30, 2027 | ERON, JOSEPH J | reporter.nih.gov |
| TASK ORDER 7 - ODP | NIH | National Institute on Drug Abuse | 2024 | $23,970,498 | May 31, 2024 | September 30, 2024 | MAYS, GARY | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $23,280,590 | August 1, 2021 | January 14, 2027 | PEKOSZ, ANDREW | reporter.nih.gov |
| Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimer’s disease in Ancestral and Admixed Populations | NIH | National Institute on Aging | 2023 to 2025 | $23,106,653 | August 15, 2023 | July 31, 2028 | DE ERAUSQUIN, GABRIEL ALEJANDRO | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $22,981,366 | December 11, 2019 | November 30, 2026 | ROUPHAEL, NADINE GEORGES | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,835,693 | July 1, 2020 | August 31, 2026 | PEVEAR, DANIEL | reporter.nih.gov |
| CENTERS FOR RESEARCH ON STRUCTURAL BIOLOGY OF INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,661,527 | September 1, 2022 | August 31, 2026 | STAKER, BART | reporter.nih.gov |
| NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,625,203 | April 1, 2021 | September 14, 2027 | TOMPKINS, S. MARK | reporter.nih.gov |
| UZ-UCSF CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,624,239 | September 9, 2025 | November 30, 2027 | CHIRENJE, ZVAVAHERA MIKE | reporter.nih.gov |
| UCLA AIDS Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,546,764 | February 1, 2007 | November 30, 2027 | LANDOVITZ, RAPHAEL J | reporter.nih.gov |
| Vaccine and Treatment Evaluation Unit at Saint Louis University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,219,564 | December 11, 2019 | November 30, 2026 | HOFT, DANIEL F. | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $21,157,224 | July 1, 2020 | January 31, 2025 | CIRZ, RYAN | reporter.nih.gov |
| New Mexico IDeA Networks of Biomedical Research Excellence (INBRE) | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $20,744,885 | September 30, 2001 | March 31, 2029 | LUSETTI, SHELLEY | reporter.nih.gov |
| CENTERS FOR RESEARCH ON STRUCTURAL BIOLOGY OF INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $20,695,869 | September 1, 2022 | August 31, 2026 | SATCHELL, KARLA | reporter.nih.gov |
| COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $20,632,183 | September 30, 2023 | September 29, 2024 | DENNY, THOMAS | reporter.nih.gov |
| International Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $20,605,531 | January 1, 2014 | November 30, 2027 | ALDROVANDI, GRACE M | reporter.nih.gov |
| BIOINFORMATICS RESOURCE CENTERS FOR INFECTIOUS DISEASES: SARS-CoV-2 ACTIVITIES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $20,255,157 | September 15, 2019 | September 14, 2024 | STEVENS, RICK | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,720,676 | September 16, 2019 | September 15, 2026 | FRANKENFIELD, JILL | reporter.nih.gov |
| ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $18,205,751 | September 19, 2022 | September 18, 2026 | SAUNDERS, KEVIN | reporter.nih.gov |
| UCSD Collaborative Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $18,116,542 | December 1, 2024 | November 30, 2027 | WILKIN, TIMOTHY J. | reporter.nih.gov |
| Development of Therapeutic Products for Antibacterial Resistant Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,380,862 | September 9, 2019 | January 31, 2026 | OSCHNER, URS | reporter.nih.gov |
| East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional Consortium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,134,028 | June 1, 2025 | June 30, 2026 | WOOLS-KALOUSTIAN, KARA KAY | reporter.nih.gov |
| Emory-CDC CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,972,899 | December 1, 2024 | November 30, 2027 | KELLEY, COLLEEN F | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component C: Clinical Core | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,914,921 | September 16, 2019 | September 30, 2026 | BERES, WENDELL | reporter.nih.gov |
| International epidemiology Databases to Evaluate AIDS (IeDEA) Southern Africa. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,840,939 | May 1, 2025 | April 30, 2027 | ROHNER, ELIANE | reporter.nih.gov |
| Center for Viral Systems Biology (CViSB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,438,330 | February 1, 2018 | January 31, 2028 | ANDERSEN, KRISTIAN GRAUGAARD | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $16,069,735 | September 22, 2022 | August 31, 2025 | CIRZ, RYAN | reporter.nih.gov |
| Central Africa International Epidemiology databases to Evaluate AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,957,495 | May 1, 2025 | April 30, 2027 | YOTEBIENG, MARCEL | reporter.nih.gov |
| DEVELOPMENT OF A VACCINE CANDIDATE FOR CORONAVIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $15,898,493 | June 1, 2023 | May 31, 2026 | KRAMMER, FLORIAN | reporter.nih.gov |
| Transmission Aerobiology of M. tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across an Evolutionary Bottleneck | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,828,159 | May 13, 2021 | April 30, 2027 | RHEE, KYU Y | reporter.nih.gov |
| C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $15,575,398 | July 1, 2024 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| Therapeutic Editing to Lower PrP in Prion Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $15,507,691 | May 17, 2023 | April 30, 2026 | VALLABH, SONIA MINIKEL | reporter.nih.gov |
| PERU Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,506,525 | December 1, 2024 | November 30, 2027 | SANCHEZ, JORGE LUIS | reporter.nih.gov |
| Caribbean, Central, and South America network for HIV Epidemiology (CCASAnet) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,404,946 | May 1, 2025 | June 30, 2026 | CASTILHO, JESSICA L | reporter.nih.gov |
| NIAID Influenza Data Processing and Communication Center: Universal Influenza Vaccine Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,386,477 | April 1, 2021 | March 31, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| PHRU-Setshaba Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,110,381 | December 1, 2024 | November 30, 2027 | GRAY, GLENDA E | reporter.nih.gov |
| EXERCISE OPTION PERIOD 1 TO PROVIDE SUPPORT FOR TECHNICAL ASSESSMENTS AND PROJECT MANAGEMENT FOR THE NIBIB RAPID ACCELERATION OF DIAGNOSTICS (RADX) IN | NIH | National Heart, Lung, and Blood Institute | 2021 | $14,996,149 | April 15, 2021 | October 14, 2021 | MARINO, MARK | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $14,810,179 | July 1, 2020 | October 19, 2025 | OCHSNER, URS ARNOLD | reporter.nih.gov |
| Hispanic Alliance for Clinical and Translational Research (Alliance) | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $14,653,051 | September 2, 2020 | June 30, 2025 | LUCIANO, CARLOS A. | reporter.nih.gov |
| CODA: COvid and Diabetes Assessment | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2024 | $14,508,027 | July 21, 2023 | June 30, 2028 | ROTHMAN, RUSSELL L. | reporter.nih.gov |
| Task A90: Establishment of a Model of Nipah Virus Infection for Assessment of Medical Countermeasures Efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,497,049 | April 15, 2024 | September 2, 2025 | BEASLEY, DAVID | reporter.nih.gov |
| Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $14,399,999 | March 26, 2024 | February 28, 2029 | SAVIC, RADOJKA | reporter.nih.gov |
| University of Rochester Vaccine and Treatment Evaluation Unit (VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,263,529 | December 11, 2019 | November 30, 2026 | FALSEY, ANN R | reporter.nih.gov |
| A prospective study of critical environmental exposures in formative early life that impact lifelong health in rural US children: the New Hampshire Birth Cohort Study | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $14,260,643 | September 21, 2016 | May 31, 2025 | KARAGAS, MARGARET RITA | reporter.nih.gov |
| 1/2 REPRIEVE Extension for Trial Completion | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $14,219,228 | May 1, 2023 | April 30, 2027 | GRINSPOON, STEVEN K. | reporter.nih.gov |
| Kaiser Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,173,633 | December 11, 2019 | November 30, 2026 | JACKSON, LISA A | reporter.nih.gov |
| Caribbean Primate Research Center Program | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $14,084,108 | April 15, 1987 | November 30, 2028 | LOPEZ, MARCOS | reporter.nih.gov |
| Center for Translational Pediatric Research | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $14,029,666 | July 11, 2017 | June 30, 2027 | TACKETT, ALAN | reporter.nih.gov |
| HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,518,599 | April 1, 2007 | November 30, 2027 | BEKKER, LINDA-GAIL | reporter.nih.gov |
| Metabolic determinants of Mtb virulence, vulnerability and variation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,485,680 | May 1, 2025 | April 30, 2027 | MOODY, DAVID BRANCH | reporter.nih.gov |
| Protective immunity following dengue virus natural infections and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,429,941 | July 29, 2015 | July 31, 2030 | HARRIS, EVA | reporter.nih.gov |
| THE PURPOSE OF THIS MODIFICATION IS TO ADD MILESTONE 1A, REVISE THE DELIVERABLES FOR MILESTONE 4-10, AND REVISE THE BASE POP TO END ON 1/18/2022. | NIH | National Heart, Lung, and Blood Institute | 2021 | $13,419,752 | June 8, 2021 | December 21, 2021 | MARINO, MARK | reporter.nih.gov |
| Trusted Training: Improving Health and Safety Through an All-Hazard Training Approach | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $13,355,376 | September 1, 1992 | May 31, 2030 | FITCH, ASHLEE | reporter.nih.gov |
| Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,340,237 | April 10, 2020 | November 30, 2026 | MULLIGAN, MARK JOSEPH | reporter.nih.gov |
| University of New Mexico Center for Metals in Biology and Medicine | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $13,321,441 | July 1, 2020 | April 30, 2030 | CAMPEN, MATTHEW J | reporter.nih.gov |
| Understanding Influenza and SARS-CoV-2 vaccine responses, in vivo and in vitro | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,884,300 | September 1, 2003 | April 30, 2029 | DAVIS, MARK MORRIS | reporter.nih.gov |
| HEALTH Center for Addictions Research and Cancer Prevention | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2024 | $12,882,144 | September 8, 2020 | April 30, 2026 | BEECH, BETTINA M. | reporter.nih.gov |
| Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,773,513 | January 17, 2018 | December 31, 2027 | WUNDERINK, RICHARD G | reporter.nih.gov |
| Vanderbilt HIV Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,733,650 | February 1, 2007 | November 30, 2027 | HAAS, DAVID W | reporter.nih.gov |
| Case Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,725,521 | December 1, 2024 | November 30, 2027 | YENDEWA, GEORGE | reporter.nih.gov |
| RADXHIV VIRAL LOAD | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $12,723,739 | September 11, 2007 | July 31, 2028 | MANABE, YUKARI C | reporter.nih.gov |
| Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,580,221 | June 1, 2025 | May 31, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Development of an Antiviral to Combat Viral Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $12,480,276 | November 15, 2022 | April 17, 2025 | CHANG, JINHONG | reporter.nih.gov |
| Columbia Collaborative HIV/AIDS Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,286,513 | February 1, 2007 | November 30, 2027 | SOBIESZCZYK, MAGDALENA ELZBIETA | reporter.nih.gov |
| Trans-omics Integration of Multi-omics Studies for Osteoporosis | NIH | National Institute on Aging | 2021 to 2025 | $12,202,183 | September 15, 2017 | June 30, 2027 | DENG, HONG-WEN | reporter.nih.gov |
| NATIONAL CLINICAL DATA COLLABORATIVE COUNTS (NACDACC) | NIH | National Institute on Drug Abuse | 2024 to 2025 | $12,127,951 | September 30, 2024 | September 29, 2025 | MAYS, GARY | reporter.nih.gov |
| Cincinnati Children's Hospital Medical Center Vaccine and Treatment Evaluation Units (UM1 Clinical Trial Required) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,115,898 | December 11, 2019 | November 30, 2026 | FRENCK, ROBERT WILSON | reporter.nih.gov |
| Center for Redox Biology and Cardiovascular Disease | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $12,065,347 | February 1, 2018 | June 30, 2028 | KEVIL, CHRISTOPHER G | reporter.nih.gov |
| TB-RICC 3.0 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $11,818,694 | April 1, 2023 | March 31, 2028 | ELLNER, JERROLD J. | reporter.nih.gov |
| RADx-Rad Discoveries & Data: Consortium Coordination Center Program Organization | NIH | National Library of Medicine | 2021 to 2022 | $11,803,325 | December 21, 2020 | November 30, 2022 | OHNO-MACHADO, LUCILA | reporter.nih.gov |
| Durable Alteration of the Human Immune system after Infection or Immunotherapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,785,761 | June 8, 2009 | May 31, 2029 | CHUNG, RAYMOND T | reporter.nih.gov |
| REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD | NIH | National Institute on Aging | 2024 to 2025 | $11,773,020 | January 1, 2024 | December 31, 2028 | ELY, E WESLEY | reporter.nih.gov |
| Task A71: Comprehensive In Vivo Screening of Viral Pathogens of Pandemic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,745,278 | July 18, 2022 | July 17, 2025 | MORREY, JOHN | reporter.nih.gov |
| Development of an Optimized Adjuvanted TB Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,645,061 | September 30, 2021 | September 30, 2025 | EVANS, JAY | reporter.nih.gov |
| WaNPRC Macaca nemestrina SPF Breeding Colony | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $11,361,503 | September 30, 2002 | June 30, 2028 | FULLER, DEBORAH H. | reporter.nih.gov |
| West African Emerging Infectious Disease Research Center (WA-EIDRC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,322,650 | May 21, 2020 | June 5, 2025 | ANDERSEN, KRISTIAN GRAUGAARD | reporter.nih.gov |
| KwaZulu-Natal Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,302,268 | December 1, 2024 | November 30, 2027 | ABDOOL KARIM, QUARRAISHA | reporter.nih.gov |
| Clinical Development of COVID-19 Therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $11,286,393 | September 22, 2023 | February 15, 2026 | WANG, STANLEY | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,268,155 | September 1, 2020 | March 31, 2027 | MALINOWSKI, FRANK | reporter.nih.gov |
| Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,202,199 | March 15, 2007 | September 21, 2025 | SANNE, IAN MATTHIAS | reporter.nih.gov |
| Mays Cancer Center at UT Health SA | NIH | National Cancer Institute | 2021 to 2025 | $11,193,809 | August 1, 1997 | July 31, 2026 | ZHENG, LEI | reporter.nih.gov |
| Emerging Infectious Diseases Research Centers Coordination Center (EIDRC CC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,018,742 | May 18, 2020 | April 30, 2025 | SEMPOWSKI, GREGORY D | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $10,977,909 | September 21, 2022 | November 8, 2024 | TOMARAS, ANDREW | reporter.nih.gov |
| Advancing Vaccine Adjuvant Research for Tuberculosis (TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,964,476 | September 30, 2022 | September 29, 2027 | BRITTON, WARWICK | reporter.nih.gov |
| Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,947,708 | February 5, 2007 | November 30, 2027 | GUPTA, AMITA | reporter.nih.gov |
| NYR-Diabetes Research Center (NYR-DRC) | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $10,878,379 | December 1, 1996 | April 30, 2030 | PESSIN, JEFFREY E. | reporter.nih.gov |
| Advanced Development of a Universal Influenza Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,853,574 | September 9, 2019 | April 24, 2025 | LOCHER, CHRISTOPHER | reporter.nih.gov |
| Reagent Program for HIV and other Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,735,388 | October 15, 2023 | January 13, 2024 | RASHID, SUJATHA | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,650,296 | September 9, 2019 | October 31, 2025 | CASPER, COREY | reporter.nih.gov |
| Administrative Supplement Request for 2025 Systems Biology for Infectious Diseases Annual Meeting | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,511,156 | August 17, 2018 | May 31, 2028 | KROGAN, NEVAN J | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, AntiMicrobial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,501,521 | May 17, 2021 | December 31, 2026 | KANE, BRIAN | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,313,540 | September 23, 2016 | March 31, 2026 | HENKEL, TIMOTHY | reporter.nih.gov |
| ADJUVANT COMPARISON AND CHARACTERIZATION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,234,165 | September 1, 2022 | January 1, 2027 | FELGNER, PHILIP | reporter.nih.gov |
| Establish a Public Private Partnership for COVID19 Research | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $10,186,691 | May 2, 2020 | February 29, 2024 | ADAM, STACEY | reporter.nih.gov |
| Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,070,868 | March 15, 2007 | November 30, 2027 | SUPPARATPINYO, KHUANCHAI | reporter.nih.gov |
| Advanced Development of Medical Countermeasures for Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,028,832 | September 9, 2019 | August 11, 2024 | TOMIC, MILAN | reporter.nih.gov |
| Advanced Development of a Multivalent Vaccine Candidate for Lassa Fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,931,387 | September 1, 2017 | January 31, 2027 | SCHNELL, MATTHIAS JOHANNES | reporter.nih.gov |
| The Military HIV Research Program (MHRP) Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,676 | December 10, 2013 | November 30, 2027 | ROBB, MERLIN L | reporter.nih.gov |
| The Johns Hopkins University - Uganda Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,249 | February 5, 2007 | November 30, 2027 | FOWLER, MARY GLENN | reporter.nih.gov |
| Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,862,919 | March 22, 2022 | February 28, 2027 | FERNANDEZ-SESMA, ANA | reporter.nih.gov |
| Botswana-Harvard T.H. Chan School of Public Health AIDS Initiative Partnership CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,824,534 | February 1, 2007 | June 30, 2025 | LOCKMAN, SHAHIN | reporter.nih.gov |
| Center for Modeling Complex Interactons | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $9,684,540 | March 15, 2015 | June 30, 2025 | WICHMAN, HOLLY A | reporter.nih.gov |
| GHESKIO Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,655,243 | February 1, 2007 | November 30, 2027 | PAPE, JEAN WILLIAM | reporter.nih.gov |
| DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $9,566,206 | September 30, 2023 | September 29, 2026 | EVANS, JAY | reporter.nih.gov |
| NCATS SECURE SCIENTIFIC PLATFORMS ENVIRONMENT SUPPORT FOR THE N3C DATA ENCLAVE, POP 12/25/2020 - 9/27/2021 | NIH | National Institute on Drug Abuse | 2021 | $9,554,920 | December 25, 2020 | September 27, 2021 | ZAVERTNICK, BRIAN | reporter.nih.gov |
| University of Washington Arboviral Research Network (UWARN) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $9,499,281 | May 22, 2020 | June 5, 2025 | VAN VOORHIS, WESLEY C | reporter.nih.gov |
| The Center for Innovation in Point-of-Care Technologies for HIV/AIDS and Emerging Infectious Diseases at Northwestern University (C-THAN) | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $9,495,667 | September 11, 2018 | July 31, 2028 | ACHENBACH, CHAD J | reporter.nih.gov |
| Development of a Novel Therapeutic for Melioidosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,235,577 | September 20, 2022 | September 30, 2026 | ALLEY, M.R.K. (DICKON) | reporter.nih.gov |
| Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,218,182 | August 24, 2022 | July 31, 2027 | BARKER, BRIDGET MARIE | reporter.nih.gov |
| The Care Ecosystem Response to COVID-19: Accelerating Research on Dementia Care that Meets the Needs of Caregivers and Persons with Dementia during COVID-19 | NIH | National Institute on Aging | 2022 to 2024 | $9,143,854 | June 15, 2022 | May 31, 2026 | POSSIN, KATHERINE LAUREL | reporter.nih.gov |
| COBRE: Eukaryotic Pathogens Innovation Center (EPIC) | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $9,118,734 | July 15, 2022 | May 31, 2027 | MORRIS, JAMES CULVIN | reporter.nih.gov |
| Understanding Risk Gradients from Environment on Native American Child Health Trajectories: Toxicants, Immunomodulation, Metabolic syndromes, & Metals Exposure | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $8,902,713 | September 21, 2016 | May 31, 2025 | MACKENZIE, DEBRA | reporter.nih.gov |
| Understanding Risk Gradients from Environment on Native American Child Health Trajectories: Toxicants, Immunomodulation, Metabolic syndromes, & Metals Exposure | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $8,860,022 | September 21, 2016 | May 31, 2030 | MACKENZIE, DEBRA | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $8,743,439 | September 25, 2023 | June 24, 2024 | RAMSTEDT, URBAN | reporter.nih.gov |
| Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Supporting Financial Sustainability, Advanced Methods, and Knowledge Translation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $8,690,640 | July 15, 2015 | April 30, 2030 | SCHACKMAN, BRUCE R | reporter.nih.gov |
| Task V34: Master Cell Banks Manufacturing for Next Generation SARS-CoV-2 Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $8,647,922 | May 15, 2018 | May 14, 2028 | TRUSHEIM, HEIDI | reporter.nih.gov |
| RADX PROGRAM: TECH PROJECT NO 6114 FLUIDIGM ADVANTA DX SARS-COV-2 RT-PCR ASSAY FOR SALIVA | NIH | National Heart, Lung, and Blood Institute | 2021 | $8,580,056 | July 30, 2020 | September 30, 2021 | QUONG, ANDREW | reporter.nih.gov |
| NCATS SCIENTIFIC AND TECHNOLOGY SUPPORT SERVICES (STSS) | NIH | National Institute on Drug Abuse | 2024 to 2025 | $8,491,687 | September 30, 2024 | January 6, 2025 | MAYS, GARY | reporter.nih.gov |
| Hyperhydration to Improve Kidney Outcomes in Children with Shiga Toxin-Producing E. Coli Infection (HIKO STEC): A Multinational, Embedded, Cluster, Crossover, Randomized Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,451,589 | September 17, 2021 | August 31, 2027 | FREEDMAN, STEPHEN BRADLEY | reporter.nih.gov |
| FEND for TB supplement to accelerate BLINK X development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $8,340,332 | June 4, 2020 | May 31, 2025 | ELLNER, JERROLD J. | reporter.nih.gov |
| San Francisco Bay Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,314,128 | March 2, 2007 | November 30, 2027 | BUCHBINDER, SUSAN | reporter.nih.gov |
| The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,239,326 | January 15, 2008 | November 30, 2027 | GRINSZTEJN, BEATRIZ | reporter.nih.gov |
| Center for American Indian and Rural Health Equity | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $8,200,764 | September 15, 2014 | August 31, 2025 | ADAMS, ALEXANDRA K. | reporter.nih.gov |
| Hazardous Materials Worker Health and Safety Training (U45), Cooperative Agreement | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $8,171,064 | September 1, 1992 | May 31, 2030 | TURCOTTE, DAVID | reporter.nih.gov |
| Disordered Proteostasis as a Driver of Disease in the Aging Lung | NIH | National Institute on Aging | 2021 to 2024 | $8,161,610 | July 1, 2015 | March 31, 2025 | BUDINGER, GR SCOTT | reporter.nih.gov |
| A deep longitudinal analysis of next generation influenza vaccines in older adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $8,127,184 | January 1, 2022 | December 31, 2026 | UCAR, DUYGU | reporter.nih.gov |
| Human Biomimetics for Mucosal Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,059,968 | March 15, 2015 | May 31, 2027 | ESTES, MARY KOLB | reporter.nih.gov |
| External Quality Assurance Program Oversight Laboratory (EQAPOL) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $7,902,910 | September 30, 2024 | September 29, 2031 | DENNY, THOMAS | reporter.nih.gov |
| Advanced Development and Clinical Evaluation of an Entamoeba Histolytica Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $7,788,182 | September 21, 2018 | November 22, 2025 | FOX, CHRISTOPHER | reporter.nih.gov |
| Integrating innate and adaptive pathways in vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $7,762,589 | April 1, 2014 | March 31, 2024 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| Seattle Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,698,581 | February 1, 2007 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| Augmenting Scientific Discovery and Research Infrastructure in the UAB Regional Biocontainment Laboratory (SEBLAB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,660,000 | September 23, 2021 | February 28, 2025 | LEAL, SIXTO MANUEL | reporter.nih.gov |
| FEND for TB | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,632,771 | June 4, 2020 | May 31, 2026 | ELLNER, JERROLD J. | reporter.nih.gov |
| The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $7,511,308 | September 10, 2021 | August 31, 2027 | SAMET, JEFFREY H. | reporter.nih.gov |
| SUPPLEMENTAL FUNDS TO PROVIDE RADX INFRASTRUCTURE SUPPORT THROUGH JULY 1, 2021 | NIH | National Heart, Lung, and Blood Institute | 2021 | $7,499,311 | July 2, 2020 | April 30, 2021 | MARINO, MARK | reporter.nih.gov |
| Advanced Development of Vaccines for Filoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,417,867 | July 21, 2020 | December 31, 2026 | ELDRIDGE, JOHN | reporter.nih.gov |
| Collaborative Influenza Vaccine Innovation Centers STATISTICAL, DATA MANAGEMENT AND COORDINATION CENTER (SDMCC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,400,390 | September 30, 2025 | September 29, 2026 | BOUR, STEPHAN | reporter.nih.gov |
| Administrative Supplements for NIAID Regional Biocontainment Laboratories (RBL) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,369,853 | September 23, 2021 | February 28, 2025 | ALEM, FARHANG | reporter.nih.gov |
| Harmonist: A Scalable Toolkit for Standardizing and Coordinating Data Sharing Across International Research Networks | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,298,694 | May 25, 2016 | April 30, 2027 | DUDA, STEPHANY NORAH | reporter.nih.gov |
| DEVELOPMENT OF VACCINES FOR INFLUENZA USING AN IMMUNO-MODULATOR ADJUVANT AND MULTI-PLATFORM APPROACH | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $7,281,050 | September 30, 2023 | September 29, 2028 | EL-KAMMASH, BRUXANNE | reporter.nih.gov |
| EpiCenter for Emerging Infectious Disease Intelligence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $7,215,074 | July 13, 2020 | June 5, 2025 | JOHNSON, CHRISTINE KREUDER | reporter.nih.gov |
| RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT NO 2375 - MASSIVELY PARALLEL CENTRALIZED AND DECENTRALIZED ULTRAFAST COVID-19INFECTIOUS | NIH | National Heart, Lung, and Blood Institute | 2021 | $7,200,049 | September 30, 2020 | September 29, 2021 | BEEBE, DAVID | reporter.nih.gov |
| The Bacterial and Viral Bioinformatics Resource Center (BV-BRC) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $7,200,000 | July 18, 2024 | June 30, 2029 | STEVENS, RICK L. | reporter.nih.gov |
| Facility Upgrade for the New England Regional Biosafety Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $7,162,679 | August 22, 2022 | February 28, 2025 | TELFORD, SAM R | reporter.nih.gov |
| Adjuvant Development of the TLR4 Ligand BECC470s For Use in Influenza, S. aureus, and P. aeruginosa Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,143,498 | September 30, 2023 | September 29, 2028 | SORENSON, GREGORY | reporter.nih.gov |
| Molecules and Pathways at the Coccidioides Host-Pathogen Interface | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,052,234 | January 1, 2022 | December 31, 2026 | SIL, ANITA | reporter.nih.gov |
| TASK ORDER B-15: Model Development and Medical Countermeasure Evaluation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $7,029,612 | October 24, 2022 | October 1, 2023 | GRIFFITHS, ANTHONY | reporter.nih.gov |
| ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,937,118 | September 30, 2023 | September 29, 2026 | COLLINS, NICOLAS | reporter.nih.gov |
| Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,892,629 | September 15, 2004 | August 31, 2025 | FARRIS, A DARISE | reporter.nih.gov |
| The Mutant Mouse Resource and Research Center at The Jackson Laboratory | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $6,802,936 | January 1, 2010 | January 31, 2030 | LUTZ, CATHLEEN M | reporter.nih.gov |
| Emerging Infectious Diseases Research Center - East and Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,734,930 | June 1, 2020 | June 5, 2025 | NJENGA, M KARIUKI | reporter.nih.gov |
| Development of a COVID-19 Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,733,518 | September 1, 2020 | October 31, 2023 | REED, STEVEN | reporter.nih.gov |
| TNPRC Regional Biocontainment Laboratory Upgrade for Capacity Building | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,714,363 | September 23, 2021 | February 28, 2025 | RAPPAPORT, JAY | reporter.nih.gov |
| Emerging infections: surveillance, epidemiology and pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,690,286 | May 11, 2020 | June 5, 2025 | WANG, DAVID | reporter.nih.gov |
| Aurum Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,678,965 | December 1, 2020 | November 30, 2027 | CHURCHYARD, GAVIN JOHN | reporter.nih.gov |
| Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,659,737 | August 22, 2022 | February 28, 2025 | DUPREX, WILLIAM PAUL | reporter.nih.gov |
| West African Center for Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,658,566 | June 9, 2020 | June 5, 2025 | WEAVER, SCOTT C | reporter.nih.gov |
| B Cell Epitope Discovery and Mechanisms of Antibody Protection: Responses to Dengue 4, Powassan, Chikungunya, and Venezuelan Equine Encephalitis Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,634,396 | September 16, 2023 | September 15, 2024 | FREMONT, DAVED | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,612,767 | September 21, 2022 | January 18, 2026 | KRUISWIJK, CORINE | reporter.nih.gov |
| Role of Data Streams In Informing Infection Dynamics in Africa- INFORM Africa | NIH | Fogarty International Center | 2021 to 2025 | $6,610,435 | September 15, 2021 | June 30, 2027 | ABIMIKU, ALASH'LE G. | reporter.nih.gov |
| Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,605,926 | December 9, 2021 | November 30, 2026 | LENG, SEAN XIAO | reporter.nih.gov |
| Administrative supplement to Duke G20 award | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,594,615 | September 23, 2021 | February 28, 2025 | STAATS, HERMAN F | reporter.nih.gov |
| Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,593,067 | September 16, 2021 | February 28, 2025 | ADAMS, ERIN JUNE | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,592,393 | September 23, 2022 | July 22, 2026 | NORTON, ELIZABETH | reporter.nih.gov |
| Task A68: Screening Vaccine (and Other Biologics) Platform Technologies using Coronavirus Mouse Immunogenicity as a Model System | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,550,363 | May 23, 2022 | September 30, 2026 | GRAHAM, RACHEL | reporter.nih.gov |
| Stellenbosch University Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,524,563 | April 15, 2007 | November 30, 2027 | HESSELING, ANNEKE CATHARINA | reporter.nih.gov |
| Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,498,374 | August 1, 2017 | July 31, 2027 | WARE, RUSSELL E | reporter.nih.gov |
| Regional Biocontainment Laboratory (RBL) Upgrade for Colorado State University (CSU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,493,184 | September 23, 2021 | February 28, 2025 | DOBOS, KAREN MARIE | reporter.nih.gov |
| Coordinating Research on Emerging Arboviral Threats Encoing the Neotropics (CREATE-NEO) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,472,246 | June 1, 2020 | June 5, 2025 | VASILAKIS, NIKOS | reporter.nih.gov |
| Small-molecule activators of STING-signaling as novel adjuvants for flavivirus vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,461,817 | September 30, 2019 | September 29, 2024 | NELSON, JAY | reporter.nih.gov |
| METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,434,161 | September 11, 2025 | August 31, 2029 | DARWIN, KATERINA HERAN | reporter.nih.gov |
| Task A82: Murine Models of UTI Caused by Antibiotic-Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,424,343 | July 19, 2023 | February 27, 2025 | GALLACHER, ANTHONY | reporter.nih.gov |
| Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA) | NIH | Fogarty International Center | 2021 to 2025 | $6,419,538 | September 15, 2021 | June 30, 2027 | HAPPI, CHRISTIAN T. | reporter.nih.gov |
| Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,398,428 | July 1, 2021 | June 30, 2027 | GENGENBACHER, MARTIN ALFONS | reporter.nih.gov |
| Protective Genetic Variants for Alzheimer Disease in the Amish - RENEWAL | NIH | National Institute on Aging | 2022 to 2025 | $6,381,039 | September 1, 2022 | May 31, 2027 | HAINES, JONATHAN L | reporter.nih.gov |
| American and Asian Centers for Arboviral Research and Enhanced Surveillance (A2CARES) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,361,142 | July 20, 2020 | May 31, 2025 | HARRIS, EVA | reporter.nih.gov |
| DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $6,359,752 | September 30, 2023 | September 29, 2028 | LAPEK, JENNIFER | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,358,495 | July 1, 2020 | July 28, 2026 | BOWLIN, TERRY | reporter.nih.gov |
| Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,330,175 | February 4, 2021 | January 31, 2026 | KAPPE, STEFAN HI | reporter.nih.gov |
| Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,328,779 | May 4, 2021 | April 30, 2027 | BOYD, STEVEN ARMEN | reporter.nih.gov |
| Mechanisms of Fecal Microbiota Transplant Protection from Recurrent C. difficile | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,326,957 | July 24, 2020 | June 30, 2029 | PETRI, WILLIAM A | reporter.nih.gov |
| Enhancing immunity to malaria in young children with effective chemoprevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,263,495 | July 1, 2025 | June 30, 2027 | JAGANNATHAN, PRASANNA | reporter.nih.gov |
| Developing Teixobactin for Respiratory Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,154,703 | March 22, 2021 | February 28, 2027 | HUGHES, DALLAS | reporter.nih.gov |
| TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,022,974 | September 30, 2019 | April 30, 2026 | CARSON, DENNIS | reporter.nih.gov |
| Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $6,015,134 | September 17, 2021 | August 31, 2025 | DEB, ARJUN | reporter.nih.gov |
| B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,936,710 | September 16, 2019 | August 31, 2025 | CROWE, JAMES E | reporter.nih.gov |
| Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,933,702 | April 8, 2021 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,907,864 | September 30, 2023 | September 29, 2028 | BURKHART, DAVID | reporter.nih.gov |
| Discovery of adjuvants via novel modulation of innate immune pathways for vaccines against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,841,904 | September 30, 2019 | April 30, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| Drivers of individual variation in influenza vaccine response and protection from infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,827,282 | July 14, 2022 | June 30, 2027 | COBEY, SARAH | reporter.nih.gov |
| Structural Genomics Centers for Infectious Diseases: SARS-CoV-2 Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $5,706,284 | September 1, 2017 | August 31, 2022 | SATCHELL, KARLA | reporter.nih.gov |
| Critical Factors Influencing Echinocandin Resistance in Candida glabrata | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,673,964 | August 1, 2014 | July 31, 2028 | PERLIN, DAVID S | reporter.nih.gov |
| Improvements to the Regional Biocontainment Research Facilities at the University of Missouri | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,667,997 | September 23, 2021 | February 28, 2025 | LORSON, CHRISTIAN L. | reporter.nih.gov |
| Improving Neonatal health Through Rapid malaria testing in Early Pregnancy with high-sensitivity Diagnostics (INTREPiD) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,664,388 | April 1, 2022 | March 31, 2027 | TAYLOR, STEVE MYER | reporter.nih.gov |
| NBER Center for Aging and Health Research | NIH | National Institute on Aging | 2021 to 2025 | $5,663,258 | August 1, 1997 | August 31, 2027 | CUTLER, DAVID M | reporter.nih.gov |
| Small-molecule inducers of the cGAS/STING pathway as novel adjuvants for flu vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,636,289 | September 30, 2019 | September 29, 2024 | ADOLFO, GARCIA-SASTRE | reporter.nih.gov |
| Task V02: Manufacture of Influenza for Human Challenge Clinical Trials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,587,695 | May 15, 2018 | May 31, 2026 | HASSEL, THOMAS | reporter.nih.gov |
| Exploiting Diversity-Oriented Chemical Synthesis for Combating Chronic Parasitic Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,580,444 | February 8, 2020 | July 31, 2030 | SIBLEY, L. DAVID | reporter.nih.gov |
| Southwest Center for Advancing Clinical and Translational Innovation (SW CACTI) | NIH | National Center for Advancing Translational Sciences | 2025 | $5,574,473 | August 1, 2025 | June 30, 2032 | PANDHI, NANCY | reporter.nih.gov |
| Comparative effectiveness and complications of intravenous ceftriaxone compared with oral doxycycline in Lyme meningitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,573,382 | September 1, 2021 | August 31, 2027 | NIGROVIC, LISE E. | reporter.nih.gov |
| DON in Pediatric Cerebral Malaria: A Phase I / II Dose-Escalation Safety Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,567,850 | June 1, 2025 | May 31, 2027 | POSTELS, DOUGLAS | reporter.nih.gov |
| Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,559,114 | June 17, 2020 | January 31, 2027 | WALZL, GERHARD | reporter.nih.gov |
| UAW Hazardous Material Worker Health and Safety Training (U45) | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $5,542,216 | September 1, 1992 | May 31, 2025 | SIVIN, DARIUS D | reporter.nih.gov |
| Inter-regional study of transmission, adaptation and pathogenesis of viruses with pandemic potential in Southeast Asia and West/Central Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,526,401 | July 17, 2020 | June 5, 2025 | SAKUNTABHAI, ANAVAJ | reporter.nih.gov |
| Alzheimer’s Disease Related Biomarkers following SARS-CoV-2 Infection | NIH | National Institute on Aging | 2022 to 2025 | $5,518,240 | June 15, 2022 | March 31, 2027 | WISNIEWSKI, THOMAS M | reporter.nih.gov |
| Advanced Development of Vaccines for Influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,495,941 | September 9, 2019 | May 31, 2027 | STAERZ, UWE | reporter.nih.gov |
| Small-molecule adjuvants testing pipeline (Influenza) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,486,225 | September 30, 2019 | September 29, 2024 | LEVY, OFER | reporter.nih.gov |
| DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,484,466 | August 21, 2020 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| IND-Enabling Studies for Arenavirus Preclinical Candidate | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,459,651 | May 13, 2021 | January 31, 2027 | SOKOLOVA, NADEZDA V | reporter.nih.gov |
| Comparative systems biology of apicomplexan cell division | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,447,470 | July 21, 2022 | June 30, 2027 | GUBBELS, MARC-JAN | reporter.nih.gov |
| Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,430,840 | April 12, 2019 | March 31, 2025 | LUETKEMEYER, ANNE FREY | reporter.nih.gov |
| DEVELOPMENT OF IN VITRO DIAGNOSTICS FOR ANTIMICROBIAL RESISTANCE ESCHERICHIA COLI | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $5,422,657 | July 24, 2023 | July 31, 2026 | SAMPATH, RANGARAJAN | reporter.nih.gov |
| Structure-Function Analysis of Mxra8 Interaction with Alphaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,414,348 | June 1, 2019 | July 31, 2029 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Cellular Immunology Core Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $5,413,068 | June 1, 2025 | May 31, 2026 | KAUR, AMITINDER | reporter.nih.gov |
| Developing computational models to predict the immune response to B. pertussis booster vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,401,756 | March 10, 2020 | February 28, 2025 | PETERS, BJOERN | reporter.nih.gov |
| Chicago Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,330,849 | February 1, 2007 | November 30, 2027 | ACHENBACH, CHAD J | reporter.nih.gov |
| STRUCTURAL GENOMICS CENTERS FOR INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $5,288,246 | September 1, 2017 | August 31, 2021 | MYLER, PETER | reporter.nih.gov |
| Implementation of a Pragmatic Trial of Whole Health Team vs. Primary Care Group Education to Promote Non-Pharmacological Strategies to Improve Pain, Function and Quality of Life in Veterans | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $5,266,106 | January 1, 2024 | December 31, 2025 | SEAL, KAREN H | reporter.nih.gov |
| Supplement to G20AI67347 to complete critical upgrades to the Rutgers RBL | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,241,770 | August 22, 2022 | February 29, 2024 | ALLAND, DAVID | reporter.nih.gov |
| UTHSC RBL Administrative Supplement For Antiviral Discovery & Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $5,233,648 | September 15, 2021 | February 28, 2025 | JONSSON, COLLEEN B | reporter.nih.gov |
| Advancement of a poxvirus antiviral | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,192,454 | March 12, 2020 | August 31, 2029 | CONNOR, JOHN H | reporter.nih.gov |
| Supplement for MINI point-of-use device | NIH | National Institute on Drug Abuse | 2021 to 2022 | $5,188,351 | July 1, 2022 | December 31, 2023 | SOLO-GABRIELE, HELENA | reporter.nih.gov |
| Development of vaccination strategies to elicit broadly protective immunity against influenza | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,165,779 | June 18, 2019 | June 30, 2029 | RAVETCH, JEFFREY VICTOR | reporter.nih.gov |
| Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD | NIH | National Institute on Aging | 2021 to 2025 | $5,121,493 | September 30, 2021 | May 31, 2027 | SPIRA, ADAM PETER | reporter.nih.gov |
| Comparison of High vs. Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,116,475 | June 9, 2023 | March 31, 2028 | HALASA, NATASHA BASSAM | reporter.nih.gov |
| LINKAGE HONEST BROKER SERVICES FOR THE N3C DATA ENCLAVE | NIH | National Institute on Drug Abuse | 2024 to 2025 | $5,114,136 | March 1, 2024 | February 28, 2025 | GRANNIS, SHAUN | reporter.nih.gov |
| Sialic acid analogs against multidrug-resistant gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,099,184 | April 20, 2021 | March 31, 2027 | RAM, SANJAY | reporter.nih.gov |
| Maternal SARS-CoV-2 infection, placenta biology, and neurodevelopmental outcomes in the offspring | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $5,085,297 | September 5, 2022 | July 31, 2027 | URSINI, GIANLUCA | reporter.nih.gov |
| DNA damage response and repair of a broken chromosome | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $5,083,668 | June 1, 2018 | May 31, 2028 | HABER, JAMES E | reporter.nih.gov |
| tRNA in codon usage | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $5,063,701 | March 1, 2020 | August 31, 2029 | HOU, YA-MING | reporter.nih.gov |
| Focal mass drug administration (fMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Peru | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,036,878 | June 1, 2025 | May 31, 2027 | HSIANG, MICHELLE SANG | reporter.nih.gov |
| Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $5,036,160 | September 1, 2022 | August 31, 2027 | CHANG, AILEEN | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $5,018,496 | July 5, 2023 | May 31, 2028 | VOIGT, EMILY | reporter.nih.gov |
| Quanitifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,011,286 | April 1, 2020 | March 31, 2026 | VAZQUEZ PROKOPEC, GONZALO MARTIN | reporter.nih.gov |
| DEVELOPMENT OF PAN-FILOVIRUS THERAPEUTICS | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,008,204 | November 1, 2022 | March 1, 2027 | BOWLIN, TERRY | reporter.nih.gov |
| Task 12: Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,969,800 | September 6, 2019 | June 30, 2026 | HOOK, EDWARD | reporter.nih.gov |
| Evaluation of an OMV-adjuvanted Chimeritrope Vaccine against Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,961,891 | September 30, 2018 | September 29, 2023 | MORICI, LISA | reporter.nih.gov |
| The "Dynamics of the immune responses to repeat influenza vaccination exposures" (DRIVE) Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,955,723 | September 11, 2020 | June 30, 2026 | COBEY, SARAH | reporter.nih.gov |
| RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROGRAM: PROJECT NO 5218 MATMACORP SARS-COV-2 HIGH THROUGHPUT LABORATORY CAPACITY SCALE-UP | NIH | National Heart, Lung, and Blood Institute | 2021 | $4,947,000 | August 29, 2020 | April 30, 2021 | KOZERA, PHIL | reporter.nih.gov |
| Bacteriophage-based approach for managing Shigella infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,946,719 | May 5, 2020 | April 30, 2026 | SULAKVELIDZE, ALEXANDER | reporter.nih.gov |
| The Historically Black Colleges/Universities and Communities Worker Health and Safety Training Program | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $4,913,625 | September 15, 2000 | May 31, 2025 | WRIGHT, BEVERLY L | reporter.nih.gov |
| Preclinical development of a vaccine for Nipah virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,912,518 | March 11, 2021 | February 28, 2027 | GEISBERT, THOMAS WILLIAM | reporter.nih.gov |
| Living in the post-Zika world: Impact of interactions between dengue and Zika viruses on diagnostics, antibody dynamics, and correlates of disease risk | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,905,886 | July 13, 2021 | April 30, 2027 | HARRIS, EVA | reporter.nih.gov |
| Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $4,889,710 | June 7, 2024 | June 1, 2026 | BRUYETTE, DAVID | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery:Global identification of epitopes derived from Zika (ZIKV), Chikungunya (CHIKV) viruses following natural infection and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,881,220 | September 30, 2019 | September 29, 2024 | MITCHELL, MAYA | reporter.nih.gov |
| Structure based design of trimer interface epitope focused universal influenza vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,864,362 | March 12, 2020 | February 28, 2025 | CROWE, JAMES E | reporter.nih.gov |
| Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,835,728 | December 1, 2020 | November 30, 2026 | ADAMS, JOHN H | reporter.nih.gov |
| Deep spatial immune profiling of granulomas and M. tuberculosis adaptation to disease and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,831,256 | December 1, 2021 | November 30, 2026 | RENGARAJAN, JYOTHI | reporter.nih.gov |
| HIV-1 Fusion Peptide-directed Vaccine Design Using Virus-like Particles | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,825,382 | March 1, 2021 | February 28, 2027 | KONG, RUI | reporter.nih.gov |
| Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,817,583 | September 24, 2021 | August 31, 2024 | RODICK, ROBERT | reporter.nih.gov |
| The economic and social impact of pandemic mitigation policies: A cross-country analysis of macro events | NIH | National Institute on Aging | 2021 to 2025 | $4,809,580 | April 15, 2021 | January 31, 2027 | LILLARD, DEAN R | reporter.nih.gov |
| Novel Stem Cell Immunotherapy for MDR-Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,800,190 | June 4, 2021 | May 31, 2026 | JAGANNATH, CHINNASWAMY | reporter.nih.gov |
| Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,799,861 | September 15, 2020 | August 31, 2025 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Rapid Research for Diagnostics Development in TB Network: Episode 2 (R2D2 TB Network II) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $4,760,584 | September 23, 2025 | August 31, 2030 | NAHID, PAYAM | reporter.nih.gov |
| Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,757,817 | November 22, 2021 | October 31, 2026 | MARASCO, WAYNE A. | reporter.nih.gov |
| Establishment of a Public-Private Partnership (PPP) to Support Therapy Selection and Testing within RECOVER-TLC | NIH | Office of the Director, National Institutes of Health | 2024 to 2025 | $4,755,161 | September 25, 2024 | December 31, 2026 | PENNINI, MEGHAN | reporter.nih.gov |
| Optimizing SARS-CoV-2 wastewater based surveillance in urban and university campus settings. | NIH | National Institute on Drug Abuse | 2021 to 2022 | $4,752,331 | January 1, 2021 | May 31, 2024 | UHLEMANN, ANNE-CATRIN | reporter.nih.gov |
| NCATS LINKAGE HONEST BROKER (LHB) - PATIENT-CENTERED OUTCOMES RESEARCH (PCOR) TRUST FUND ASPE NATIONAL COVID-19 LONGITUDINAL RESEARCH DATABASE LINKED | NIH | National Institute on Drug Abuse | 2022 | $4,742,386 | March 1, 2022 | February 28, 2023 | TACHINARDI, UMBERTO | reporter.nih.gov |
| Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,717,265 | April 1, 2021 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,716,636 | May 1, 2025 | April 30, 2027 | KOENIG, SERENA PATRICIA | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,706,565 | September 21, 2022 | April 30, 2027 | THAMMAVONGSA, VILASACK | reporter.nih.gov |
| DEVELOPMENT OF SAPONIN DMLT ADJUVANT (SDA) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,695,387 | September 30, 2023 | September 29, 2026 | NORTON, ELIZABETH | reporter.nih.gov |
| COVID-19 Mother Baby Outcomes (COMBO): brain-behavior functioning | NIH | National Institute of Mental Health | 2021 to 2025 | $4,681,303 | April 12, 2021 | January 31, 2027 | DUMITRIU, DANI | reporter.nih.gov |
| Mechanisms of innate immune dysfunction in SIV/malaria co-infection in pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $4,672,308 | September 24, 2021 | July 31, 2026 | MANUZAK, JENNIFER | reporter.nih.gov |
| Development and Support of the Pathway Tools Software | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,665,041 | May 12, 2021 | April 30, 2026 | KARP, PETER D | reporter.nih.gov |
| Heritable immunization of the white-footed mouse reservoir of Lyme disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,657,626 | September 1, 2021 | August 31, 2026 | ESVELT, KEVIN | reporter.nih.gov |
| Clinical Trial Site Monitoring for PHOENIx MDR-TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,653,435 | April 15, 2025 | December 14, 2025 | SMITH, KIMBERLY | reporter.nih.gov |
| DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,647,135 | June 29, 2020 | May 31, 2026 | ANTIA, RUSTOM NOSHIR | reporter.nih.gov |
| IgE antibodies to the mammalian oligosaccharide galactose-alpha-1, 3-galactose (alpha-gal): immunology, epidemiology and relevance to allergic and inflammatory disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,621,686 | July 1, 1984 | May 31, 2028 | PLATTS-MILLS, THOMAS A. | reporter.nih.gov |
| MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,608,548 | January 1, 2023 | December 31, 2023 | COFFIN, JEANETTE | reporter.nih.gov |
| New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,603,680 | September 5, 2019 | August 31, 2025 | DAIGLE, DENIS MARC | reporter.nih.gov |
| A functional evolutionary genetic approach to combat viral infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,591,708 | September 30, 2020 | July 31, 2026 | SCHOGGINS, JOHN W. | reporter.nih.gov |
| Development of In Vitro Diagnostics for the Detection of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $4,590,862 | June 1, 2023 | May 31, 2025 | SCHAUS, SCOTT | reporter.nih.gov |
| Development of the INI-4001 and INI-2002 adjuvants within the context of a vaccine to prevent Lyme disease. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,583,801 | September 30, 2018 | September 29, 2024 | EVANS, JAY | reporter.nih.gov |
| Tissue factor-dependent coagulation in thrombosis and immune responses | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,577,076 | February 1, 2021 | January 31, 2028 | MACKMAN, NIGEL | reporter.nih.gov |
| Upgrading infectious disease research facilities at University of Louisville RBL | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $4,553,002 | August 22, 2022 | February 28, 2025 | PALMER, KENNETH E | reporter.nih.gov |
| Coordinate Regulation of Virulence in Vibrio Cholerae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,541,366 | July 1, 1981 | March 31, 2029 | MEKALANOS, JOHN JOSEPH | reporter.nih.gov |
| Long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzaniav | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,537,676 | April 15, 2022 | March 31, 2027 | HSIANG, MICHELLE SANG | reporter.nih.gov |
| T cell recognition of the MR1 presented microbial metabolome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,523,152 | July 10, 2019 | June 30, 2025 | ADAMS, ERIN JUNE | reporter.nih.gov |
| Development of a handheld rapid air sensing system to monitor and quantify SARS-CoV-2 in aerosols in real-time | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2023 | $4,504,502 | June 1, 2023 | August 31, 2025 | MANCEBO, RICARDO | reporter.nih.gov |
| Impact of tuberculosis on the development and function of the immune system in SIV-infected infants | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $4,476,086 | April 1, 2019 | March 31, 2025 | WANG, XIAOLEI | reporter.nih.gov |
| Understanding Risk of Zoonotic Virus Emergence in EID Hotspots of Southeast Asia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,474,707 | June 17, 2020 | May 15, 2024 | DASZAK, PETER | reporter.nih.gov |
| Discovering antimicrobials acting against MDR pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,469,088 | September 2, 2022 | August 31, 2026 | LEWIS, KIM | reporter.nih.gov |
| Regulation of Protein C Pathways | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,441,427 | June 1, 2018 | March 31, 2026 | MOSNIER, LAURENT OLIVIER | reporter.nih.gov |
| A systems analysis of drug tolerance in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,414,678 | December 1, 2016 | June 30, 2027 | BALIGA, NITIN S | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units: Wolbachia-Infected Aedes aegypti Mosquitos in Reducing Arboviral Infection Brazil | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,402,306 | February 4, 2020 | November 30, 2027 | ROUPHAEL, NADINE | reporter.nih.gov |
| Molecular Analysis and Lineage Tracing of Influenza-Specific, Lung-Resident Memory B Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,398,832 | April 7, 2020 | March 31, 2027 | RANDALL, TROY D | reporter.nih.gov |
| Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: the Kentucky Viral Hepatitis Treatment (KeY Treat) Study | NIH | National Institute on Drug Abuse | 2021 to 2023 | $4,371,481 | September 30, 2018 | July 31, 2025 | HAVENS, JENNIFER R | reporter.nih.gov |
| Unraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,354,000 | September 30, 2020 | July 31, 2025 | VEESLER, DAVID | reporter.nih.gov |
| DIGITAL HEALTH SOLUTIONS FOR COVID-19: PERSONALIZED ANALYTICS WEARABLE BIOSENSOR PLATFORM FOR EARLY DETECTION OF COVID-19 DECOMPENSATION | NIH | National Cancer Institute | 2021 | $4,338,693 | September 14, 2020 | September 13, 2021 | LARIMER, KAREN | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,323,930 | September 29, 2019 | September 29, 2025 | GAGE, KASIA | reporter.nih.gov |
| NRSA Training Core | NIH | National Center for Advancing Translational Sciences | 2021 to 2025 | $4,317,682 | June 1, 2017 | February 28, 2027 | MOORE, MEGAN | reporter.nih.gov |
| VACCINES ADJUVANT DEVELOPMENT PROGRAM IN INFECTIOUS AND IMMUNE MEDIATED DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,300,145 | September 30, 2023 | September 29, 2026 | DOWLING, DAVID JAMES | reporter.nih.gov |
| PROJECT MANAGEMENT SUPPORT FOR COMMUNITY ENGAGEMENT ON TRANS-NIH THERAPEUTICS AND VACCINE TRIALS | NIH | National Heart, Lung, and Blood Institute | 2021 | $4,297,649 | July 29, 2020 | January 28, 2021 | SHINGLEDECKER, DANIEL | reporter.nih.gov |
| Viral and immune-mediated CNS pathology during SARS-CoV-2 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,269,302 | July 24, 2020 | June 30, 2025 | IWASAKI, AKIKO | reporter.nih.gov |
| Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB Study | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,248,593 | July 1, 2025 | June 30, 2027 | AULD, SARA | reporter.nih.gov |
| Preventing TB with intravenous BCG in SIV-infected macaques | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,248,442 | May 5, 2021 | April 30, 2026 | SCANGA, CHARLES A. | reporter.nih.gov |
| Influenza pathogenesis in pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,248,239 | June 14, 2021 | May 31, 2027 | ADAMS WALDORF, KRISTINA M. | reporter.nih.gov |
| Task C24: Process Optimization and Scale Up of an Antibiotic-Resistant Bacterial Agent | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,247,326 | July 19, 2024 | January 18, 2026 | SCHLAGER, HEIDI | reporter.nih.gov |
| Development and Testing of New Computational Methods for Ligand Discovery and Mechanism | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,227,565 | June 1, 2017 | August 31, 2027 | SHOICHET, BRIAN K | reporter.nih.gov |
| Mechanism, Function, and Exploitation of Influenza A Virus-Activated Cell Death | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,220,934 | September 25, 2017 | August 31, 2027 | BALACHANDRAN, SIDDHARTH | reporter.nih.gov |
| Targeting innate immune pathways, and inflammatory cell death in cytokine-mediated diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,212,442 | June 15, 2021 | May 31, 2026 | KANNEGANTI, THIRUMALA-DEVI | reporter.nih.gov |
| Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections(AMR), and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $4,211,973 | September 18, 2024 | September 17, 2029 | LENIGK, RALF | reporter.nih.gov |
| The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,208,331 | June 1, 2020 | July 31, 2030 | SESHADRI, CHETAN | reporter.nih.gov |
| The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,204,220 | May 15, 2015 | June 30, 2030 | FLEXNER, CHARLES W. | reporter.nih.gov |
| A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx | NIH | National Institute of Mental Health | 2021 to 2025 | $4,199,975 | June 1, 2021 | May 31, 2027 | ALPERT, JONATHAN EDWARD | reporter.nih.gov |
| Capturing spatial patterns of new M. tuberculosis infection in Kampala, Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,188,624 | August 9, 2019 | July 31, 2026 | BARK, CHARLES MARTYN | reporter.nih.gov |
| Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients | NIH | National Center for Advancing Translational Sciences | 2021 to 2022 | $4,174,965 | April 6, 2021 | April 5, 2023 | KIL, JONATHAN | reporter.nih.gov |
| Structural Analysis and Inhibitor Optimization of Cryptosporidium n-myristoyltransferase for Drug Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,163,372 | November 15, 2020 | October 31, 2026 | STAKER, BART LEE | reporter.nih.gov |
| Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,152,012 | February 1, 2023 | January 31, 2027 | KHADER, SHABAANA A. | reporter.nih.gov |
| Structure and Dynamics of the SARS-CoV-2 Spike Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,142,443 | July 12, 2021 | June 30, 2027 | MOTHES, WALTHER H | reporter.nih.gov |
| Programmable benchtop bioreactors for scalable eco-evolutionary dynamics of the human microbiome | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,135,886 | June 10, 2022 | May 31, 2027 | KHALIL, AHMAD SAMIR | reporter.nih.gov |
| DIGITAL HEALTH SOLUTIONS FOR COVID-19: DIGITAL HEALTH PASS AND SMARTER CONTACT TRACING SOLUTIONS | NIH | National Cancer Institute | 2021 | $4,135,490 | September 14, 2020 | September 13, 2021 | GOETZEL, RON | reporter.nih.gov |
| Longitudinal Study of HIV and Aging in Brazil | NIH | National Institute on Aging | 2021 to 2025 | $4,122,466 | August 15, 2021 | April 30, 2027 | CASTILHO, JESSICA L | reporter.nih.gov |
| Development of mRNA-platform vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,121,318 | January 21, 2021 | December 31, 2026 | DAMRON, FREDRICK HEATH | reporter.nih.gov |
| Mechanisms of Helicases, Translocases and SSB Proteins involved in Genome Maintenance | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,120,970 | May 1, 2020 | July 31, 2030 | LOHMAN, TIMOTHY M | reporter.nih.gov |
| The role of CD40L in resistance to enteric infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,118,859 | August 17, 2021 | May 31, 2026 | HUNTER, CHRISTOPHER A | reporter.nih.gov |
| Impact of Care Delivery and Therapeutic Changes on Patients with Alzheimer's Disease and Alzheimer's Disease Related Dementias | NIH | National Institute on Aging | 2021 to 2025 | $4,115,749 | September 30, 2021 | May 31, 2027 | HSU, JOHN | reporter.nih.gov |
| Computational examination of RDoC threat and reward constructs in a representative, predominantly low-income, longitudinal sample at increased risk for internalizing disorders (Admin Supplement) | NIH | National Institute of Mental Health | 2021 to 2024 | $4,115,209 | August 15, 2019 | June 30, 2025 | MONK, CHRISTOPHER STEPHEN | reporter.nih.gov |
| Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,114,200 | February 10, 2022 | January 31, 2027 | WILDER, BRANDON KEITH | reporter.nih.gov |
| Development of an oral liver-targeted prime-and-trap malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,104,491 | December 1, 2020 | November 30, 2026 | MURPHY, SEAN C | reporter.nih.gov |
| A STINGing vaccine for TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,090,805 | June 1, 2020 | May 31, 2026 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Childhood Omics and Mycobacterium tuberculosis-derived BiOsignatures (COMBO) for TB diagnosis in high HIV prevalence settings | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $4,076,080 | April 22, 2020 | August 31, 2025 | CATTAMANCHI, ADITHYA | reporter.nih.gov |
| Parasitic Ulcer Treatment Trial | NIH | National Eye Institute | 2023 to 2025 | $4,068,111 | September 30, 2023 | March 31, 2028 | KEENAN, JEREMY DAVID | reporter.nih.gov |
| Optimization of Lead BKIs for Cryptosporidiosis Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,065,300 | January 1, 2021 | December 31, 2026 | VAN VOORHIS, WESLEY C | reporter.nih.gov |
| Mosquito SAMSP1 and SAMSP2 influence the initial stage of Plasmodium infection of mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,052,693 | April 14, 2021 | March 31, 2027 | FIKRIG, EROL | reporter.nih.gov |
| Molecular elucidation of the Francisella tularensis virulence mechanism | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,049,782 | May 21, 2021 | April 30, 2027 | SCHUMACHER, MARIA | reporter.nih.gov |
| Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,042,959 | January 25, 2023 | December 31, 2027 | LOUIE, ARNOLD | reporter.nih.gov |
| Structure/Function of Transcription Complex Regulation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,041,062 | July 1, 1987 | August 31, 2027 | LANDICK, ROBERT | reporter.nih.gov |
| Innovations in Functional B Cell Epitope Discovery for Lyme Disease | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $4,031,164 | September 16, 2024 | September 15, 2026 | MANTIS, NICHOLAS | reporter.nih.gov |
| Defining functional humoral correlates of immunity to guide vaccine design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,023,233 | November 24, 2020 | October 31, 2025 | BATISTA, FACUNDO DAMIAN | reporter.nih.gov |
| The BASIC trial: Improving implementation of evidence-based approaches and surveillance to prevent bacterial transmission and infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,005,071 | June 17, 2021 | May 31, 2027 | BROWN, JEREMIAH R | reporter.nih.gov |
| Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,981,418 | July 9, 2021 | December 31, 2026 | BAKER, SUSAN C. | reporter.nih.gov |
| RADX TECH - CERES NANOSCIENCE INC NANOTRAP PARTICLE MANUFACTURING | NIH | National Heart, Lung, and Blood Institute | 2021 | $3,974,000 | August 28, 2020 | May 31, 2021 | DUNLAP, ROSS | reporter.nih.gov |
| Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,970,913 | July 1, 2021 | June 30, 2027 | GOLENBOCK, DOUGLAS T | reporter.nih.gov |
| MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,967,038 | July 13, 2021 | June 30, 2027 | HOLLENBACH, JILL ALLISON | reporter.nih.gov |
| Wastewater Detection of COVID-19 | NIH | National Institute on Drug Abuse | 2021 to 2022 | $3,962,927 | January 1, 2021 | May 31, 2024 | WENZEL, JEFF | reporter.nih.gov |
| Prevention, Preparedness, and Response (P2R) Consortium | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $3,962,435 | August 17, 2010 | May 31, 2030 | RIOS, JANELLE | reporter.nih.gov |
| Establishment of a Bat Resource for Infectious Disease Research | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $3,960,972 | September 22, 2023 | August 31, 2028 | SCHOUNTZ, WILLIAM A | reporter.nih.gov |
| Selecting HA glycosylation for improved vaccine responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,957,417 | June 9, 2021 | May 31, 2027 | ZAIA, JOSEPH | reporter.nih.gov |
| Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,954,829 | April 15, 2011 | June 30, 2027 | ICHTCHENKO, KONSTANTIN | reporter.nih.gov |
| Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,950,305 | March 1, 2017 | July 31, 2025 | LIPKA, ELKE | reporter.nih.gov |
| World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,949,988 | February 1, 2016 | March 24, 2025 | WEAVER, SCOTT C | reporter.nih.gov |
| Cryo-EM of Helical Protein and Nucleoprotein Polymers at Near Atomic Resolution | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,949,496 | May 1, 2017 | April 30, 2027 | EGELMAN, EDWARD H. | reporter.nih.gov |
| Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,937,392 | September 20, 2022 | July 31, 2027 | RONG, LIJUN | reporter.nih.gov |
| Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,773 | July 1, 2021 | April 30, 2027 | DUNCAN, JOSEPH A | reporter.nih.gov |
| Structure of amyloid fibrils in human neurodegenerative diseases and aging | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $3,924,261 | September 30, 2018 | August 31, 2026 | VIDAL, RUBEN | reporter.nih.gov |
| A systems immunology approach to evaluate malaria vaccine performance in endemic regions of Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,921,000 | February 1, 2022 | January 31, 2027 | MOORMANN, ANN M | reporter.nih.gov |
| Next generation mosquito control through technology-driven trap development and artificial intelligence guided detection of mosquito breeding habitats | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,914,766 | September 17, 2021 | August 31, 2026 | NOLAN, MELISSA SUZANNE | reporter.nih.gov |
| Mechanisms of Prion Protein Toxicity | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,903,115 | July 1, 2010 | June 30, 2026 | HARRIS, DAVID A | reporter.nih.gov |
| Novel Pediatric Sepsis Criteria and Clinical Decision Support Tools | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,901,596 | September 1, 2021 | May 31, 2030 | BENNETT, TELLEN | reporter.nih.gov |
| Understanding Co-morbidities: COVID-19 in individuals living with HIV/AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,900,756 | February 1, 2022 | January 31, 2027 | SINGH, DHIRAJ KUMAR | reporter.nih.gov |
| Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,892,523 | August 20, 2021 | July 31, 2025 | AZOITEI, MIHAI LUCHIAN | reporter.nih.gov |
| Discovery of Adjuvants for mRNA Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,882,045 | September 30, 2025 | September 29, 2026 | CARSON, DENNIS | reporter.nih.gov |
| Dietary and synbiotic strategy to limit gut microbiome dysbiosis and protect against Clostridioides difficile infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,880,251 | April 23, 2021 | March 31, 2027 | LOZUPONE, CATHERINE | reporter.nih.gov |
| Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,877,163 | April 6, 2021 | March 31, 2027 | VAKULENKO, SERGEI | reporter.nih.gov |
| Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,876,556 | March 15, 2021 | February 28, 2027 | HORWITZ, MARCUS AARON | reporter.nih.gov |
| Psychosocial Stress due to COVID-19 and Vascular Aging in African-American Women | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,866,300 | May 1, 2021 | March 31, 2026 | LEWIS, TENÉ T | reporter.nih.gov |
| Making Better Decisions: Policy Modeling for AIDS and Drug Abuse | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,865,844 | September 25, 2022 | January 31, 2029 | OWENS, DOUGLAS K | reporter.nih.gov |
| Cellular and molecular programming of lung resident T cell memory | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,857,630 | May 1, 2020 | April 30, 2027 | KOHLMEIER, JACOB E | reporter.nih.gov |
| Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,856,328 | September 1, 2019 | August 31, 2029 | LIN, GANG | reporter.nih.gov |
| Developing broad-spectrum therapeutics against C. difficile toxins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,852,231 | February 11, 2021 | January 31, 2027 | JIN, RONGSHENG | reporter.nih.gov |
| Optimization of novel phenotypic screening hits for treatment of Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,843,960 | April 1, 2021 | March 31, 2027 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| At the Intersection of HIV and COVID-19: Medicaid Data as a Complement to Cohort Studies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,843,434 | June 10, 2022 | May 31, 2027 | LAU, BRYAN | reporter.nih.gov |
| Mechanisms of protection against shigellosis in children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,843,317 | June 9, 2022 | May 31, 2027 | PASETTI, MARCELA F | reporter.nih.gov |
| Skin biomarkers for diagnosing and characterizing AD and ADRD | NIH | National Institute on Aging | 2021 to 2025 | $3,834,262 | September 30, 2021 | June 30, 2027 | KRAUS, ALLISON L | reporter.nih.gov |
| Ribosome Structure and Function | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,829,940 | April 1, 2016 | March 31, 2027 | NOLLER, HARRY F | reporter.nih.gov |
| Optimizing a small molecule inhibitor of SARS-CoV-2 replication and associated cytokine storm | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,828,356 | September 1, 2021 | August 31, 2026 | GLENN, JEFFREY S | reporter.nih.gov |
| New antifungals targeting the synthesis of fungal sphingolipids | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,827,282 | December 1, 2015 | March 31, 2026 | DEL POETA, MAURIZIO | reporter.nih.gov |
| Identification of novel immunogenic proteins from Bordetella pertussis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,825,567 | June 9, 2021 | May 31, 2027 | DUBEY, PURNIMA | reporter.nih.gov |
| Immune Dysfunction in HIV+ Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,823,539 | April 15, 2020 | January 31, 2027 | PAHWA, SAVITA | reporter.nih.gov |
| Understanding Pandemic Evolution through Networked Data (UPEND) | NIH | National Institute of Mental Health | 2023 | $3,822,251 | April 15, 2023 | April 14, 2026 | CROWELL, TREVOR ADAM | reporter.nih.gov |
| Functional profiling of OSP-specific and other antibodies during shigella infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,818,268 | September 22, 2020 | August 31, 2030 | RYAN, EDWARD T. | reporter.nih.gov |
| Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,809,183 | August 1, 2015 | July 31, 2030 | LARSEN, MICHELLE H | reporter.nih.gov |
| Sleep and health disparities among Asian Americans: roles of stressors and protective factors | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $3,796,997 | April 8, 2021 | January 31, 2027 | LEE, SUNMIN | reporter.nih.gov |
| Cell competition in pulmonary fibrosis and ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,796,920 | August 20, 2022 | July 31, 2029 | DE LANGHE, STIJN PIET JOHAN | reporter.nih.gov |
| Task B24: Production of Well Characterized Challenge Material (WCCM) of High Priority Viral Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,793,148 | February 29, 2024 | January 24, 2026 | TAMHANKAR, MANASI | reporter.nih.gov |
| Point-of-care C-reactive protein-based tuberculosis screening in people living with HIV: a randomized trial | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,789,374 | September 15, 2019 | May 31, 2025 | YOON, CHRISTINA | reporter.nih.gov |
| LDLRAD3 Receptor Interaction with Venezuelan Equine Encephalitis Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,787,436 | July 1, 2021 | June 30, 2027 | DIAMOND, MICHAEL S | reporter.nih.gov |
| Immune response to COVID-19 vaccine in HIV infected men and women | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,779,701 | September 23, 2021 | August 31, 2026 | RINALDO, CHARLES R | reporter.nih.gov |
| Mechanism and Inhibition of SARS-CoV-2 Entry | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,776,105 | July 8, 2021 | June 30, 2026 | WHELAN, SEAN PJ | reporter.nih.gov |
| Genetic Investigation of Covid 19 in Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,774,284 | August 1, 2022 | July 31, 2027 | KAHN, MARK L | reporter.nih.gov |
| O-Specific Polysaccharide Responses and Cholera | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,758,033 | August 7, 2013 | March 31, 2030 | RYAN, EDWARD T. | reporter.nih.gov |
| Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,755,681 | September 17, 2021 | August 31, 2026 | ZANONI, IVAN | reporter.nih.gov |
| Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,749,095 | August 1, 2021 | May 31, 2027 | LUSTIGMAN, SARA | reporter.nih.gov |
| Evolution and inhibition of carbapenemase in beta-lactam resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,748,354 | April 6, 2021 | March 31, 2027 | CHEN, YU | reporter.nih.gov |
| Immunity to Cryptosporidium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,739,027 | January 1, 2020 | December 31, 2029 | HUNTER, CHRISTOPHER A | reporter.nih.gov |
| Validating the Flavivirus Envelope Protein as an Antiviral Target | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,735,490 | March 1, 2020 | February 28, 2026 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| Bacteria and Host in TB Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,731,271 | April 10, 2020 | March 31, 2023 | ALLAND, DAVID | reporter.nih.gov |
| Sex specific immune response to SARS-CoV-2 leads to chronic neurologic symptoms | NIH | National Institute of Mental Health | 2021 to 2025 | $3,727,455 | September 15, 2021 | July 31, 2026 | MCCULLOUGH, LOUISE D. | reporter.nih.gov |
| Heterosubtypic immunity to influenza virus mediated by MHC-E-restricted memory NK cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,727,019 | September 24, 2021 | August 31, 2027 | JOST, STEPHANIE | reporter.nih.gov |
| Covid-19 Effects on Children & Families: 2021 Follow-Up of the PSID Child Development Supplement | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,726,095 | May 1, 2021 | February 28, 2026 | SASTRY, NARAYAN | reporter.nih.gov |
| DMID REGULATORY AFFAIRS SUPPORT | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $3,723,712 | July 1, 2015 | June 30, 2022 | BUTLER, SANDRA | reporter.nih.gov |
| Lead Optimization of DHODH Inhibitors for Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,721,559 | January 1, 2013 | June 30, 2028 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| Enteric Pathogen Force of Infection among Children using Serology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,719,600 | July 1, 2021 | June 30, 2027 | ARNOLD, BENJAMIN F | reporter.nih.gov |
| Discovery of Adjuvants that Direct T-cell Fates for Improved Safety and Efficacy in Vaccines Against Influenza and Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,714,524 | September 30, 2025 | September 29, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,713,909 | August 21, 2019 | July 31, 2025 | KIRKPATRICK, BETH DIANE | reporter.nih.gov |
| Structure-based design of broad flavivirus immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,710,975 | September 24, 2021 | August 31, 2026 | LAI, JONATHAN R. | reporter.nih.gov |
| Functional B-cell Epitope Discovery for Arthropod-Borne Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,708,329 | September 16, 2024 | September 15, 2027 | reporter.nih.gov | |
| Inborn errors of immunity in patients with life-threatening COVID-19 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,707,765 | July 12, 2021 | June 30, 2026 | CASANOVA, JEAN-LAURENT | reporter.nih.gov |
| Integrating epidemiologic and environmental approaches to understand and predict Coccidioides exposure and coccidioidomycosis emergence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,707,638 | December 9, 2019 | November 30, 2025 | REMAIS, JUSTIN V | reporter.nih.gov |
| Identification and Characterization of Entry Factors Critical for Rift Valley Fever Virus Infection and Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,704,381 | March 19, 2021 | February 28, 2027 | AMARASINGHE, GAYA K. | reporter.nih.gov |
| Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,702,250 | April 1, 2024 | March 31, 2025 | MIDDLETON, MARK | reporter.nih.gov |
| Flipped Germinal Centers | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,701,340 | September 17, 2021 | August 31, 2026 | WESEMANN, DUANE R. | reporter.nih.gov |
| Research Program Award (R35 Clinical Trial Optional) - Dr. Robyn Klein NINDS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,695,974 | May 1, 2021 | October 31, 2024 | CAIN, MATTHEW D | reporter.nih.gov |
| Leveraging genomic data to dissect the association of internalizing disorders with the risk, onset, and vulnerability of COVID-19 | NIH | National Institute of Mental Health | 2022 | $3,694,722 | September 1, 2022 | August 31, 2025 | POLIMANTI, RENATO | reporter.nih.gov |
| Immunometabolic impact of stress hyperglycemia on tuberculosis treatment outcomes and risk of diabetes mellitus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,694,016 | March 4, 2021 | February 28, 2027 | MAGEE, MATTHEW JAMES | reporter.nih.gov |
| Mtb and HIV/SIV antigen peptide signatures as blood biomarkers to detect early infection to active disease in young children and NHP | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,693,137 | May 1, 2021 | March 31, 2027 | LYON, CHRISTOPHER J | reporter.nih.gov |
| DEVELOPMENT OF ANTIVIRALS FOR SPECIFIC RNA VIRAL FAMILIES OF PANDEMIC POTENTIAL | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $3,692,037 | September 22, 2023 | December 31, 2025 | HENKEL, GREG | reporter.nih.gov |
| Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,690,863 | September 20, 2022 | July 31, 2027 | MELANDER, CHRISTIAN COREY | reporter.nih.gov |
| Understanding the long term impact of COVID-19 on the brain through advanced MR imaging and spectroscopy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,689,933 | July 15, 2021 | June 30, 2026 | OZ, GULIN | reporter.nih.gov |
| Malaria across borders: Measuring imported infections and contributions to local transmission in Uganda and Zimbabwe | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,679,817 | June 16, 2021 | May 31, 2027 | RODRÍGUEZ-BARRAQUER, ISABEL | reporter.nih.gov |
| Neurodevelopment after postnatal Zika virus infection in infant macaques | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,679,627 | January 1, 2021 | November 30, 2026 | CHAHROUDI, ANN M | reporter.nih.gov |
| Mapping spatiotemporal dynamics during enterovirus infection across cells and tissues | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,677,462 | March 10, 2022 | February 28, 2027 | ANDINO, RAUL | reporter.nih.gov |
| Severe Malaria And Risk to The Brain (SMART Brain) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,674,964 | April 15, 2008 | January 31, 2029 | JOHN, CHANDY C. | reporter.nih.gov |
| Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,665,742 | April 13, 2021 | March 31, 2027 | KREBS, SHELLY J | reporter.nih.gov |
| Mapping the genomic and molecular mechanisms of antifungal resistance in the emerging fungal pathogen Candida auris | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,661,637 | March 6, 2023 | February 29, 2028 | ROGERS, P. DAVID | reporter.nih.gov |
| Advancing the development of a novel class of small molecules for treating pan-coronavirus infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,659,295 | August 10, 2021 | July 31, 2027 | EINAV, SHIRIT | reporter.nih.gov |
| PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,656,578 | March 24, 2021 | July 31, 2027 | MACLEOD, IAIN JAMES | reporter.nih.gov |
| Modeling and design of complex RNA structures | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,656,040 | September 1, 2017 | July 31, 2027 | DAS, RHIJU | reporter.nih.gov |
| The Bring BPaL2Me Trial - Comparing Nurse-Led RR-TB Treatment in Primary Care to Physician-Led, Hospital-Based RR-TB Treatment: A Cluster Randomized, Non-Inferiority Trial | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,655,506 | March 10, 2023 | February 29, 2028 | FARLEY, JASON EDWARD | reporter.nih.gov |
| Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2024 | $3,648,087 | September 25, 2021 | August 31, 2025 | GUSTAFSON, DAVID H | reporter.nih.gov |
| Fosinopril analogs for the treatment of human babesiosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,646,365 | April 21, 2021 | March 31, 2027 | BEN MAMOUN, CHOUKRI | reporter.nih.gov |
| Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,639,039 | August 1, 2021 | July 31, 2027 | MOSCONA, ANNE | reporter.nih.gov |
| Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,631,144 | March 4, 2019 | February 28, 2025 | SCANGA, CHARLES A. | reporter.nih.gov |
| Post COVID-19 Neuro-Cognitive Manifestations and Underlying Mechanisms in Older African Americans | NIH | National Institute on Aging | 2022 | $3,612,360 | August 20, 2022 | July 31, 2025 | HAJJAR, IHAB M | reporter.nih.gov |
| Mechanisms of cough in Mycobacterium tuberculosis transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,611,276 | March 8, 2021 | February 28, 2026 | SHILOH, MICHAEL | reporter.nih.gov |
| Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,610,454 | August 5, 2021 | July 31, 2025 | RENGARAJAN, JYOTHI | reporter.nih.gov |
| DEVELOPMENT OF A VACCINE CANDIDATE FOR DRUG-RESISTANT FUNGAL INFECTIONS | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,605,418 | September 30, 2025 | June 1, 2030 | NABORS, GARY | reporter.nih.gov |
| Fusion inhibitors that block host-to-host transmission of SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,603,355 | August 1, 2021 | July 31, 2027 | POROTTO, MATTEO | reporter.nih.gov |
| Development of ureadepsipetides for drug-resistant infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,597,406 | December 17, 2018 | November 30, 2024 | LAFLEUR, MICHAEL | reporter.nih.gov |
| Mechanistic registry to study whether infection with Corona Virus Disease 2019 (COVID-19) accelerates atherosclerotic plaque progression | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,595,504 | February 1, 2022 | June 30, 2026 | SHAW, LESLEE J | reporter.nih.gov |
| Molecular Analysis of Host Immune Response in Leprosy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,593,035 | January 1, 1991 | May 31, 2029 | MODLIN, ROBERT L | reporter.nih.gov |
| Development of a Replicon RNA-based Vaccine against Dengue and Zika | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,590,945 | June 1, 2021 | May 31, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Optimizing the dose of tafenoquine for the radical cure of Plasmodium vivax malaria in Southeast Asia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,588,034 | September 8, 2023 | August 31, 2028 | CHU, CINDY S | reporter.nih.gov |
| Sample-to-Answer, Rapid, Multiplexed and PCR-Free Diagnostics of Arboviral Diseases in Resource Limited Settings | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,579,220 | December 23, 2020 | November 30, 2026 | YANIK, AHMET ALI | reporter.nih.gov |
| Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,575,135 | December 24, 2018 | November 30, 2024 | BRANCO, LUIS MANUEL | reporter.nih.gov |
| Computational and Biophysical Analysis of the Filovirus Matrix Protein System | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,559,101 | August 1, 2021 | July 31, 2026 | STAHELIN, ROBERT VIRGIL | reporter.nih.gov |
| Novel mechanisms regulating immunity to respiratory virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,546,288 | August 2, 2023 | July 31, 2027 | PAUST, SILKE | reporter.nih.gov |
| Chronic Wasting Disease Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,544,335 | July 8, 2021 | June 30, 2027 | MATHIASON, CANDACE K. | reporter.nih.gov |
| The generation and protective function of lung tissue resident memory T cells following SARS-CoV-2 infection or vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,543,436 | March 1, 2022 | February 28, 2027 | TEIJARO, JOHN ROSS | reporter.nih.gov |
| Biophysical studies of macromolecules and molecular assemblies | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,542,462 | July 1, 2016 | July 31, 2026 | BOXER, STEVEN G. | reporter.nih.gov |
| Defining the cell and molecular basis of Toxoplasma recrudescence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,537,428 | January 15, 2021 | December 31, 2025 | WILSON, EMMA H | reporter.nih.gov |
| Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers | NIH | National Cancer Institute | 2021 to 2024 | $3,536,890 | April 1, 2020 | September 30, 2025 | AMBINDER, RICHARD FREDERICK | reporter.nih.gov |
| Adjuvant Development Program in the context of vaccines to protect against Y. pestis and Shigella. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,532,934 | September 30, 2018 | September 29, 2023 | ERNST, ROBERT | reporter.nih.gov |
| SARS-CoV-2 and Precursors of Alzheimer's Disease and Related Dementias: An Ultrahigh Field (7T) MRI Study in a Diverse Multinational Cohort | NIH | National Institute on Aging | 2021 | $3,529,440 | September 1, 2021 | August 31, 2025 | SESHADRI, SUDHA | reporter.nih.gov |
| Genetic, structural and functional profiling of the human antibody response to arenavirus infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,529,436 | August 22, 2022 | July 31, 2027 | BRINEY, BRYAN | reporter.nih.gov |
| Defining adaptive immune responses to Mtb-infection and TB disease among young children with and without HIV-exposure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,527,794 | April 15, 2021 | March 31, 2027 | LANCIONI, CHRISTINA LOUISE | reporter.nih.gov |
| Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,521,872 | August 1, 2024 | July 31, 2029 | BARBIER, MARIETTE | reporter.nih.gov |
| Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,518,508 | February 16, 2021 | January 31, 2027 | KOHUT, MARIAN L | reporter.nih.gov |
| Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systems | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,517,747 | June 1, 2021 | February 28, 2027 | KHALILI, MANDANA | reporter.nih.gov |
| Control of intestinal innate immunity by the commensal microbiota in a model host | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,511,902 | September 24, 2021 | August 31, 2027 | WATNICK, PAULA I | reporter.nih.gov |
| Host-pathogen interactions in experimental cholera | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,506,027 | January 1, 1998 | May 31, 2027 | WALDOR, MATTHEW K | reporter.nih.gov |
| De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,504,899 | August 2, 2021 | July 31, 2026 | BAKER, DAVID | reporter.nih.gov |
| The Tick Immune Response During Microbial Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,501,084 | December 1, 2015 | May 31, 2027 | PEDRA, JOAO | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Research Triangle Institute | Research Triangle Park, NC | 10 | $984.8 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 62 | $749 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 62 | $652 million | 0 | $0 |
| Duke University | Durham, NC | 121 | $478.1 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 22 | $448.3 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 203 | $381.3 million | 0 | $0 |
| Emory University | Atlanta, GA | 148 | $287.8 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 153 | $278.1 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 17 | $273.5 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 85 | $259.8 million | 0 | $0 |
| University of Washington | Seattle, WA | 167 | $230.1 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 37 | $224.5 million | 0 | $0 |
| Washington University | Saint Louis, MO | 166 | $203.9 million | 0 | $0 |
| Technical Resources International, Inc. | Bethesda, MD | 4 | $201.8 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 67 | $191.8 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 137 | $183.5 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 133 | $181.4 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 125 | $176.3 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 35 | $171.2 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 92 | $161.1 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 31 | $157.8 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 104 | $152 million | 0 | $0 |
| The Emmes Company, LLC | Rockville, MD | 2 | $151.1 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 43 | $141.9 million | 0 | $0 |
| Yale University | New Haven, CT | 122 | $141.5 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 133 | $139 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 80 | $136.7 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 91 | $134.1 million | 0 | $0 |
| Stanford University | Stanford, CA | 94 | $127.3 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 100 | $114.2 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 74 | $111.3 million | 0 | $0 |
| University of Chicago | Chicago, IL | 49 | $107.8 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 88 | $104.1 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 90 | $103.4 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 6 | $99.4 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 57 | $98 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 65 | $95.1 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 83 | $86.2 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 87 | $84.9 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 55 | $84.7 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 55 | $83.6 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 61 | $83.3 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 40 | $80.6 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 50 | $78.5 million | 0 | $0 |
| Axle Informatics, LLC | North Bethesda, MD | 8 | $78 million | 0 | $0 |
| American Type Culture Collection | Manassas, VA | 5 | $77.7 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 65 | $76.9 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 84 | $75.7 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 56 | $75.5 million | 0 | $0 |
| Ohio State University | Columbus, OH | 77 | $73.5 million | 0 | $0 |
| University of California at Davis | Davis, CA | 87 | $73.3 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 56 | $69.7 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 53 | $63.9 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 43 | $62.8 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 39 | $62.7 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 26 | $60.7 million | 0 | $0 |
| University of Florida | Gainesville, FL | 71 | $59.9 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 46 | $59.6 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 58 | $58.8 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 19 | $57 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 39 | $56.6 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 18 | $56 million | 0 | $0 |
| Venatorx Pharmaceuticals, Inc. | Malvern, PA | 11 | $56 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 59 | $55.3 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 48 | $54.7 million | 0 | $0 |
| Rockefeller University | New York, NY | 25 | $52.8 million | 0 | $0 |
| Cornell University | Ithaca, NY | 57 | $50.4 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 47 | $49.2 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 23 | $49 million | 0 | $0 |
| University of Rochester | Rochester, NY | 34 | $47.9 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 24 | $45.6 million | 0 | $0 |
| Rbhs-New Jersey Medical School | Newark, NJ | 43 | $44.8 million | 0 | $0 |
| West Virginia University Research Corporation | Morgantown, WV | 8 | $44.3 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 42 | $42.2 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 35 | $41.5 million | 0 | $0 |
| Palantir Technologies, Inc. | Denver, CO | 3 | $40 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 34 | $39.4 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 37 | $39 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 55 | $39 million | 0 | $0 |
| National Collegiate Inventors and Innovators Alliance | Hadley, MA | 5 | $38.5 million | 0 | $0 |
| Revagenix, Inc. | San Mateo, CA | 2 | $37.2 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 34 | $37.2 million | 0 | $0 |
| University of South Florida | Tampa, FL | 33 | $37.1 million | 0 | $0 |
| University of Montana | Missoula, MT | 10 | $34.8 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 34 | $34.7 million | 0 | $0 |
| Battelle Memorial Institute | Columbus, OH | 5 | $34.6 million | 0 | $0 |
| Texas Biomedical Research Institute | San Antonio, TX | 29 | $34.6 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 37 | $33.5 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 23 | $33.1 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 23 | $32.6 million | 0 | $0 |
| Crestone, Inc. | Boulder, CO | 3 | $32.5 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 33 | $32 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 22 | $31.8 million | 0 | $0 |
| University of Puerto Rico Med Sciences | San Juan, PR | 3 | $31.5 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 20 | $31.3 million | 0 | $0 |
| Wits Health Consortium (pty), LTD | Parktown | 6 | $31 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 12 | $30 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 34 | $29.5 million | 0 | $0 |
| Virginia Polytechnic Institute and State University | Blacksburg, VA | 47 | $29.3 million | 0 | $0 |
| Arizona State University | Scottsdale, AZ | 26 | $29.2 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 3,337 | $2,370,784,683 | 0 | $0 |
| 2024 | 3,567 | $2,899,131,409 | 0 | $0 |
| 2023 | 3,663 | $3,249,303,069 | 0 | $0 |
| 2022 | 3,966 | $3,299,799,561 | 0 | $0 |
| 2021 | 4,182 | $3,742,680,001 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.